How much did Trans Genic achieve in EBIT for the current year?
In the current year, Trans Genic has achieved an EBIT of 89.44 M JPY.
In 2024, Trans Genic's EBIT was 89.44 M JPY, a -455.61% increase from the -25.15 M JPY EBIT recorded in the previous year.
YEAR | EBIT (undefined JPY) |
---|---|
2024 | 0.09 |
2023 | -0.03 |
2022 | 1.84 |
2021 | 0.89 |
2020 | 0.17 |
2019 | 0.27 |
2018 | 0.06 |
2017 | 0.15 |
2016 | 0.05 |
2015 | 0.01 |
2014 | -0.09 |
2013 | -0.04 |
2012 | -0.13 |
2011 | -0.3 |
2010 | -0.39 |
2009 | -0.62 |
2008 | -0.64 |
2007 | -0.67 |
2006 | -0.92 |
2005 | -1.3 |
3 years
5 years
10 years
25 Years
Max
Gain insights into Trans Genic, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Trans Genic from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Trans Genic’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of Trans Genic. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into Trans Genic’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing Trans Genic’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Trans Genic’s growth potential.
Date | Trans Genic Revenue | Trans Genic EBIT | Trans Genic Net Income |
---|---|---|---|
2024 | 13.08 B undefined | 89.44 M undefined | 4.09 M undefined |
2023 | 11.43 B undefined | -25.15 M undefined | -409.67 M undefined |
2022 | 12.58 B undefined | 1.84 B undefined | 1.88 B undefined |
2021 | 11.05 B undefined | 893.2 M undefined | 546.29 M undefined |
2020 | 11.05 B undefined | 173.77 M undefined | -440.72 M undefined |
2019 | 8.67 B undefined | 270.06 M undefined | 202.22 M undefined |
2018 | 3.6 B undefined | 60.55 M undefined | 20.9 M undefined |
2017 | 2.3 B undefined | 153.95 M undefined | 80.69 M undefined |
2016 | 2.29 B undefined | 50.41 M undefined | 14.59 M undefined |
2015 | 1.96 B undefined | 12.32 M undefined | 17.82 M undefined |
2014 | 1.62 B undefined | -85 M undefined | -113.6 M undefined |
2013 | 704.1 M undefined | -36.4 M undefined | 27 M undefined |
2012 | 608 M undefined | -127.7 M undefined | -156.2 M undefined |
2011 | 509.1 M undefined | -298.8 M undefined | -215.5 M undefined |
2010 | 604 M undefined | -385.2 M undefined | -579 M undefined |
2009 | 324.9 M undefined | -624.2 M undefined | -634.9 M undefined |
2008 | 332.8 M undefined | -644.6 M undefined | -884.5 M undefined |
2007 | 435.6 M undefined | -671 M undefined | -664.2 M undefined |
2006 | 470.1 M undefined | -920.3 M undefined | -964.3 M undefined |
2005 | 640.2 M undefined | -1.3 B undefined | -1.36 B undefined |
Revenue | EBIT | Net Income | |
---|---|---|---|
2005 | 640.2 M JPY | -1.3 B JPY | -1.36 B JPY |
2006 | 470.1 M JPY | -920.3 M JPY | -964.3 M JPY |
2007 | 435.6 M JPY | -671 M JPY | -664.2 M JPY |
2008 | 332.8 M JPY | -644.6 M JPY | -884.5 M JPY |
2009 | 324.9 M JPY | -624.2 M JPY | -634.9 M JPY |
2010 | 604 M JPY | -385.2 M JPY | -579 M JPY |
2011 | 509.1 M JPY | -298.8 M JPY | -215.5 M JPY |
2012 | 608 M JPY | -127.7 M JPY | -156.2 M JPY |
2013 | 704.1 M JPY | -36.4 M JPY | 27 M JPY |
2014 | 1.62 B JPY | -85 M JPY | -113.6 M JPY |
2015 | 1.96 B JPY | 12.32 M JPY | 17.82 M JPY |
2016 | 2.29 B JPY | 50.41 M JPY | 14.59 M JPY |
2017 | 2.3 B JPY | 153.95 M JPY | 80.69 M JPY |
2018 | 3.6 B JPY | 60.55 M JPY | 20.9 M JPY |
2019 | 8.67 B JPY | 270.06 M JPY | 202.22 M JPY |
2020 | 11.05 B JPY | 173.77 M JPY | -440.72 M JPY |
2021 | 11.05 B JPY | 893.2 M JPY | 546.29 M JPY |
2022 | 12.58 B JPY | 1.84 B JPY | 1.88 B JPY |
2023 | 11.43 B JPY | -25.15 M JPY | -409.67 M JPY |
2024 | 13.08 B JPY | 89.44 M JPY | 4.09 M JPY |
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the Trans Genic's sales revenue. A higher gross margin percentage indicates that the Trans Genic retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the Trans Genic's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the Trans Genic's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Trans Genic's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Trans Genic. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Trans Genic's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Trans Genic Gross margin | Trans Genic Profit margin | Trans Genic EBIT margin | Trans Genic Profit margin |
---|---|---|---|
2024 | 17.19 % | 0.68 % | 0.03 % |
2023 | 17.45 % | -0.22 % | -3.58 % |
2022 | 30.5 % | 14.61 % | 14.92 % |
2021 | 25.14 % | 8.09 % | 4.95 % |
2020 | 16.11 % | 1.57 % | -3.99 % |
2019 | 17.27 % | 3.11 % | 2.33 % |
2018 | 22.84 % | 1.68 % | 0.58 % |
2017 | 32.52 % | 6.68 % | 3.5 % |
2016 | 29.37 % | 2.2 % | 0.64 % |
2015 | 33.54 % | 0.63 % | 0.91 % |
2014 | 31.61 % | -5.25 % | -7.02 % |
2013 | 38.84 % | -5.17 % | 3.83 % |
2012 | 37.48 % | -21 % | -25.69 % |
2011 | 46.63 % | -58.69 % | -42.33 % |
2010 | 38.21 % | -63.77 % | -95.86 % |
2009 | 52.63 % | -192.12 % | -195.41 % |
2008 | 47.18 % | -193.69 % | -265.78 % |
2007 | 47.38 % | -154.04 % | -152.48 % |
2006 | 33.06 % | -195.77 % | -205.13 % |
2005 | 64.23 % | -202.48 % | -212.01 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2005 | 64.23 % | -202.48 % | -212.01 % |
2006 | 33.06 % | -195.77 % | -205.13 % |
2007 | 47.38 % | -154.04 % | -152.48 % |
2008 | 47.18 % | -193.69 % | -265.78 % |
2009 | 52.63 % | -192.12 % | -195.41 % |
2010 | 38.21 % | -63.77 % | -95.86 % |
2011 | 46.63 % | -58.69 % | -42.33 % |
2012 | 37.48 % | -21 % | -25.69 % |
2013 | 38.84 % | -5.17 % | 3.83 % |
2014 | 31.61 % | -5.25 % | -7.02 % |
2015 | 33.54 % | 0.63 % | 0.91 % |
2016 | 29.37 % | 2.2 % | 0.64 % |
2017 | 32.52 % | 6.68 % | 3.5 % |
2018 | 22.84 % | 1.68 % | 0.58 % |
2019 | 17.27 % | 3.11 % | 2.33 % |
2020 | 16.11 % | 1.57 % | -3.99 % |
2021 | 25.14 % | 8.09 % | 4.95 % |
2022 | 30.5 % | 14.61 % | 14.92 % |
2023 | 17.45 % | -0.22 % | -3.58 % |
2024 | 17.19 % | 0.68 % | 0.03 % |
Trans Genic's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
A yearly comparison of Trans Genic's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Trans Genic's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Fluctuations in Trans Genic’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
In the current year, Trans Genic has achieved an EBIT of 89.44 M JPY.
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Trans Genic.
The EBIT of Trans Genic has increased by -455.61% decreased compared to the previous year.
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
The EBIT of Trans Genic is listed in the income statement.
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
Over the past 12 months, Trans Genic paid a dividend of 3 JPY . This corresponds to a dividend yield of about 1.29 %. For the coming 12 months, Trans Genic is expected to pay a dividend of 3 JPY.
The current dividend yield of Trans Genic is 1.29 %.
Trans Genic pays a quarterly dividend. This is distributed in the months of April, April, April, April.
Trans Genic paid dividends every year for the past 4 years.
For the upcoming 12 months, dividends amounting to 3 JPY are expected. This corresponds to a dividend yield of 1.29 %.
Trans Genic is assigned to the 'Health' sector.
To receive the latest dividend of Trans Genic from 6/1/2024 amounting to 3 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2024.
The last dividend was paid out on 6/1/2024.
In the year 2023, Trans Genic distributed 2 JPY as dividends.
The dividends of Trans Genic are distributed in JPY.
Our stock analysis for Trans Genic Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Trans Genic Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.